title: Identification and characterization of a novel gene that is upregulated in leukaemia cells by nitric oxide.
abstract: Nitric oxide (NO) inhibits growth and induces differentiation in acute myeloid leukaemia (AML) cells. To identify genes associated with these processes, we studied the effect of NO on AML gene expression using the technique of Representational Difference Analysis. Exposure of HL-60 cells to the NO donor DETA-NO for 24 h induced the expression of a novel gene that was named rno (regulated by nitric oxide). Treatment of HL-60 cells with dimethyl sulphoxide induced expression of rno, but treatment with Vitamin D3 or all-trans retinoic acid did not. Upregulation of rno by NO was cGMP independent. Northern blot analysis indicated that constitutive expression of the novel gene was limited to leucocytes. Three isoforms of rno were identified. An rno cDNA clone was obtained by screening a human leucocyte library. The nucleotide sequence of the open reading frame shared significant homology with that of the human ribonuclease/angiogenin inhibitor (RI). The predicted amino acid sequence indicated that, like RI, rno is leucine and cysteine rich and is comprised of a series of repetitive elements (leucine-rich repeats) that may mediate macromolecular interactions. Enhancement of expression of rno may be a component of the process by which differentiation and growth inhibition of leukaemia cells is induced by NO.
authors.affiliation: Division of Oncology, Department of Medicine, University of Utah School of Medicine and the Veterans Affairs Medical Center, Salt Lake City, UT 84148, USA. P.Shami@m.cc.utah.edu
authors.forename: P J
authors.initials: PJ
authors.lastname: Shami
authors.forename: N
authors.initials: N
authors.lastname: Kanai
authors.forename: L Y
authors.initials: LY
authors.lastname: Wang
authors.forename: T M
authors.initials: TM
authors.lastname: Vreeke
authors.forename: C H
authors.initials: CH
authors.lastname: Parker
mesh_terms: D015124:8-Bromo Cyclic Adenosine Monophosphate / Q000494:pharmacology; D000208:Acute Disease; D000595:Amino Acid Sequence; D001483:Base Sequence; D015152:Blotting, Northern; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005786:Gene Expression Regulation / Q000187:drug effects*; D006162:Guanylate Cyclase / Q000037:antagonists & inhibitors; D018922:HL-60 Cells / Q000187:drug effects; D006801:Humans; D007951:Leukemia, Myeloid / Q000235:genetics*; D007962:Leukocytes / Q000378:metabolism*; D008969:Molecular Sequence Data; D020030:Nitric Oxide Donors / Q000494:pharmacology*; D020033:Protein Isoforms / Q000235:genetics; D011506:Proteins / Q000235:genetics*; D020449:Repetitive Sequences, Amino Acid; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012259:Ribonuclease, Pancreatic / Q000037:antagonists & inhibitors / Q000235:genetics; D012689:Sequence Homology, Nucleic Acid; D013463:Sulfuric Acid Esters / Q000494:pharmacology; D014226:Triazenes / Q000494:pharmacology*
chemical_list: C105351:1-hydroxy-2-oxo-3,3-bis(2-aminoethyl)-1-triazene; D004791:Enzyme Inhibitors; D020030:Nitric Oxide Donors; D020033:Protein Isoforms; D011506:Proteins; D013463:Sulfuric Acid Esters; D014226:Triazenes; D015124:8-Bromo Cyclic Adenosine Monophosphate; C046366:angiogenin; D012259:Ribonuclease, Pancreatic; D006162:Guanylate Cyclase; C007482:dimethyl sulfate